Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma

NCT07673367 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Mantle Cell Lymphoma
Refractory Mantle Cell Lymphoma

Interventions

DRUG: Nemtabrutinib
DRUG: Brexucabtagene autoleucel ( other names: brexu-cel , Tecartus)

Sponsor

Vanderbilt-Ingram Cancer Center

Collaborators

[object Object]